1. Home
  2. PLUN vs KRRO Comparison

PLUN vs KRRO Comparison

Compare PLUN & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PLUN

Plutonian Acquisition Corp II

N/A

Current Price

$10.10

Market Cap

141.6M

Sector

N/A

ML Signal

N/A

Logo Korro Bio Inc.

KRRO

Korro Bio Inc.

SELL

Current Price

$9.31

Market Cap

142.0M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
PLUN
KRRO
Founded
2024
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
141.6M
142.0M
IPO Year
2026
2019

Fundamental Metrics

Financial Performance
Metric
PLUN
KRRO
Price
$10.10
$9.31
Analyst Decision
Strong Buy
Analyst Count
0
11
Target Price
N/A
★ $20.20
AVG Volume (30 Days)
43.3K
★ 196.7K
Earning Date
N/A
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $6,392,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$56.67
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 181.46
52 Week Low
$9.95
$5.20
52 Week High
$10.15
$50.45

Technical Indicators

Market Signals
Indicator
PLUN
KRRO
Relative Strength Index (RSI) 56.61 40.09
Support Level $10.07 $8.29
Resistance Level $10.15 $9.59
Average True Range (ATR) 0.01 0.73
MACD -0.00 -0.00
Stochastic Oscillator 44.44 43.03

Price Performance

Historical Comparison
PLUN
KRRO

About PLUN Plutonian Acquisition Corp II

Plutonian Acquisition Corp II is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities.

About KRRO Korro Bio Inc.

Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.

Share on Social Networks: